Get the Stockscreener App
2.81
41.21%
0.82
Cognition Therapeutics Inc stock is traded at $2.81, with a volume of 20.74M.
It is up +41.21% in the last 24 hours and up +262.44% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.99
Open:
$2.01
24h Volume:
20.74M
Relative Volume:
2.38
Market Cap:
$206.46M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-3.557
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
+82.47%
1M Performance:
+262.44%
6M Performance:
+381.82%
1Y Performance:
+270.47%
1-Day Range:
$2.01
$2.87
1-Week Range:
$1.40
$2.87
52-Week Range:
$0.2223
$2.87
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
2.81 | 109.47M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cogitation Therapeutics Gears Up for Promising Phase 3 Trials - StocksToTrade
Drawdown in Cognition Therapeutics Inc. May Be Nearing EndRate Hike & Entry and Exit Point Strategies - thegnnews.com
Press Release: Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - 富途牛牛
Should you avoid Cognition Therapeutics Inc. stock right nowWeekly Investment Recap & Risk Adjusted Buy and Sell Alerts - newsyoung.net
Cognition Therapeutics Reports Q2 2025 Financial Results - TipRanks
Cognition Therapeutics (CGTX) Soars 32.8% on FDA Alignment Hype: Is This a Biotech Breakout or a Volatility Trap? - AInvest
CGTX Plunges 10.66% Despite FDA Boost - AInvest
CGTX Stock Surge: Deciphering the Spike - StocksToTrade
CGTX Surges 21% on FDA Green Light: Is This the Catalyst for a Biotech Breakout? - AInvest
Cognition Therapeutics stock jumps after FDA confirms Phase 3 design By Investing.com - Investing.com Nigeria
Cognition Therapeutics stock jumps after FDA confirms Phase 3 design - Investing.com
Is CGTX Stock About to Skyrocket? - timothysykes.com
CGTX Soars 34.55% on FDA Phase 3 Trial Endorsement - AInvest
Cognition Therapeutics Inc. (CGTX) Soars 25.45% on FDA Trial Endorsement - AInvest
Cognition Therapeutics shares rise 32.73% premarket after FDA confirms Phase 3 program design for Alzheimer's treatment. - AInvest
Cognition Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CGTX - Benzinga
Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug - Benzinga
Cognition Therapeutics shares rise 22.73% premarket after FDA aligns on Phase 3 program for Alzheimer’s treatment. - AInvest
Regulatory Clarity and Accelerated Path to Commercialization: Cognition Therapeutics' Strategic Position in Alzheimer's Therapeutics - AInvest
Cognition Therapeutics Receives End-of-Phase 2 Meeting - GlobeNewswire
Cognition Therapeutics shares rise 30% after-hours following FDA alignment on Phase 3 program for Alzheimer’s treatment. - AInvest
Cognition Therapeutics rises on FDA support for late-stage trials of Alzheimer’s drug - TradingView
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease - The Manila Times
Cognition Therapeutics aligns with FDA on Alzheimer’s drug phase 3 design - Investing.com Nigeria
Cognition Therapeutics aligns with FDA on Alzheimer’s drug phase 3 design By Investing.com - Investing.com South Africa
Breakthrough Alzheimer's Drug Zervimesine Advances to Phase 3 with Novel Blood Test Strategy - Stock Titan
Cognition (CGTX) Surges 21.7% on Biotech Sector Volatility: What’s Fueling the Rally? - AInvest
Cognition Therapeutics Maintains Buy Rating Amid Regulatory Milestones and Promising Developments - AInvest
Alzheimer's disease Clinical Trials, Companies, Therapeutic - openPR.com
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape - Barchart.com
Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics - TipRanks
Cognition Therapeutics Reports Positive Q2 Earnings, Advances Clinical Programs for Neurodegenerative Disorders - AInvest
Cognition Therapeutics shares rise 6.35% premarket after reporting financial results and progress in Alzheimer’s disease program. - AInvest
Cognition Therapeutics Reports Q2 2025 GAAP Grant Income of $7.1mln, Exceeding Analyst Expectations - AInvest
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics reports Q2 EPS (11c), consensus (10c) - TipRanks
Cognition Therapeutics Reports Q2 2025 Results, Highlights Clinical Progress - AInvest
Cognition Therapeutics: Pivotal Alzheimer's Milestones and Strategic Pathways to Value Creation in 2025 - AInvest
Cognition Therapeutics Reports Financial Results for the - GlobeNewswire
Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs - Stock Titan
Published on: 2025-08-05 16:54:31 - beatles.ru
Top Risks to Consider Before Buying Cognition Therapeutics Inc. StockWeekly Chart Analysis With Entry Advice Provided - metal.it
Is Cognition Therapeutics Inc. a good long term investmentCapitalize on momentum-driven stocks - Jammu Links News
What are the latest earnings results for Cognition Therapeutics Inc.Invest confidently with real-time updates - Jammu Links News
What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Superior profit margins - Jammu Links News
What makes Cognition Therapeutics Inc. stock price move sharplyMaximize returns with disciplined trading approaches - Jammu Links News
Is it the right time to buy Cognition Therapeutics Inc. stockTriple-digit returns - Jammu Links News
Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionFree Daily Trading Room Entry - Jammu Links News
How volatile is Cognition Therapeutics Inc. stock compared to the marketBreakthrough capital growth - Jammu Links News
What analysts say about Cognition Therapeutics Inc. stockDynamic growth stocks - Jammu Links News
What institutional investors are buying Cognition Therapeutics Inc. stockAchieve rapid returns with smart investment plans - jammulinksnews.com
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):